Search Result

Results for "

glucose-induced

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GLUT (1) SGLT (1) Antibiotic (1) Apoptosis (4) Autophagy (2) Bacterial (1) Bcl-2 Family (1) c-Myc (2) Calcium Channel (1) Caspase (1) CGRP Receptor (1) Dipeptidyl Peptidase (1) DNA/RNA Synthesis (1) Endogenous Metabolite (1) GCGR (4) Glycosidase (1) GnRH Receptor (2) HDAC (1) Insulin Receptor (1) Interleukin Related (1) Keap1-Nrf2 (1) Na+/K+ ATPase (1) Neuropeptide Y Receptor (1) Phospholipase (1) PI3K (2) PKC (2) Reactive Oxygen Species (4) Ser/Thr Protease (1) Topoisomerase (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (5) Endocrinology (1) Infection (1) Inflammation/Immunology (7) Metabolic Disease (18) Neurological Disease (5)

By Targets:

GLUT (1)

SGLT (1)

Antibiotic (1)

Apoptosis (4)

Autophagy (2)

Bacterial (1)

Bcl-2 Family (1)

c-Myc (2)

Calcium Channel (1)

Caspase (1)

CGRP Receptor (1)

Dipeptidyl Peptidase (1)

DNA/RNA Synthesis (1)

Endogenous Metabolite (1)

GCGR (4)

Glycosidase (1)

GnRH Receptor (2)

HDAC (1)

Insulin Receptor (1)

Interleukin Related (1)

Keap1-Nrf2 (1)

Na+/K+ ATPase (1)

Neuropeptide Y Receptor (1)

Phospholipase (1)

PI3K (2)

PKC (2)

Reactive Oxygen Species (4)

Ser/Thr Protease (1)

Topoisomerase (1)

By Research Areas:

Cancer (5)

Cardiovascular Disease (5)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (7)

Metabolic Disease (18)

Neurological Disease (5)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: GLUT SGLT PINK1/Parkin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108611

AACOCF3 3 Publications Verification Arachidonyl trifluoromethyl ketone	Phospholipase	Cardiovascular Disease
AACOCF3 (Arachidonyl trifluoromethyl ketone) is a cell-permeant trifluoromethyl ketone analog of arachidonic acid. AACOCF3 is a potent and selective slow binding inhibitor of the 85-kDa cytosolic phospholipase A2 (cPLA2). AACOCF3 blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. AACOCF3 inhibits glucose-induced insulin secretion from isolated rat islets. AACOCF3 has the potential for the research of cardiovascular disease .

HY-P0054

GLP-1(7-36), amide acetate 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide acetate; Human GLP-1 (7-36), amide acetate	GCGR	Metabolic Disease
GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

HY-P0054B

GLP-1(7-36), amide TFA 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide TFA; Human GLP-1 (7-36), amide TFA	GCGR	Metabolic Disease
GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells .

HY-P3863

Pancreastatin (swine)	Ser/Thr Protease	Inflammation/Immunology
Pancreastatin (swine) is a 49-residue peptide which strongly inhibits glucose-induced insulin release. Pancreastatin (swine) can be isolated and characterized from porcine pancreas .

HY-P1401

Protein Kinase C (19-36)	PKC	Metabolic Disease
Protein Kinase C (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C (PKC), with an IC₅₀ of 0.18 μM. Protein Kinase C (19-36) markedly attenuated vascular hyperproliferation and hypertrophy as well as glucose-induced suppression of natriuretic peptide receptor response .

HY-P1072

PHM-27 (human)	CGRP Receptor	Cardiovascular Disease Metabolic Disease
PHM-27 (human) is a human prepro-vasoactive intestinal polypeptide (27 amino acid). PHM-27 (human) is a potent the human calcitonin receptor agonist with an EC₅₀ of 11 nM. PHM-27 (human) efficiently enhances glucose-induced insulin secretion from beta cells by an autocrine mechanism .

HY-P0262

Galantide	Neuropeptide Y Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
Galantide, a non-specific galanin receptor antagonist, is a peptide consisting of fragments of galanin and substance P. Galantide recognizes two classes of galanin binding sites (K_D<0.1 nM and ~6 nM) in the rat hypothalamus. Galantide dose dependently (IC₅₀=1.0 nM) antagonizes the galanin-mediated inhibition of the glucose-induced insulin secretion from mouse pancreatic islets. Galantide appears to bind to a single population of SP receptors (K_D~40 nM) .

HY-P2534

C-Peptide 2, rat	Insulin Receptor	Metabolic Disease
C-Peptide 2, rat, 31-amino-acid peptide, is a component of proinsulin. C-Peptide 2, rat can inhibit glucose-induced insulin secretion .

HY-169251

α-Glucosidase-IN-75	Glycosidase	Cardiovascular Disease Metabolic Disease
α-Glucosidase-IN-75 (compound 13) is an α-glucosidase inhibitor with an IC₅₀ of 3.81 μM. α-Glucosidase-IN-75 can be used for the study of high glucose-induced cardiovascular diseases .

HY-N8466

(-)-Lyoniresinol 9'-O-glucoside	Reactive Oxygen Species	Metabolic Disease
(-)-Lyoniresinol 9'-O-glucoside is an inhibitor of ROS. (-)-Lyoniresinol 9'-O-glucoside reduces lipid accumulation and lipid metabolic disorders in FFAs-exposed HepG2 cells. (-)-Lyoniresinol 9'-O-glucoside inhibits high glucose-induced reactive oxygen species production .

HY-129297

CMPF	Endogenous Metabolite	Metabolic Disease
CMPF can be found in trace constituent of urine and blood. CMPF is a biomarker of type 2 diabetes. CMPF can act on the β cell and induces impaired mitochondrial function. CMPF decreases glucose-induced ATP accumulation, and induces oxidative stress. CMPF reverses hepatic lipid accumulation and improves insulin sensitivity in obese mice .

HY-13413

Tofogliflozin hydrate 4 Publications Verification CSG-452 hydrate	SGLT Reactive Oxygen Species	Metabolic Disease
Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific *sodium/glucose* cotransporter 2 (SGLT2) inhibitor with an IC₅₀ of 2.9 nM and K_i values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse SGLT2** . Tofogliflozin partially inhibits high glucose-induced reactive oxyen species (ROS) generation in tubular cells .

HY-126415

Magnesium Lithospermate B	Na+/K+ ATPase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Magnesium Lithospermate B, is a derivative of caffeic acid tetramer and an inhibitor of Na+/K+ ATPase, which can be extracted from Salviae miltiorrhizae. Magnesium Lithospermate B is widely used for the research of cardiovascular diseases, and it can protect against glucose-induced intracellular oxidative damage. Magnesium Lithospermate B also suppresses neuroin?ammation and attenuates neurodegeneration .

HY-108600

CGP-53353 DAPH-7	PKC DNA/RNA Synthesis	Cardiovascular Disease Metabolic Disease
CGP-53353 (DAPH-7) is an potent PKC inhibitor with IC₅₀s of 0.41 μM and 3.8 μM for PKCβII and PKCβI, respectively. CGP-53353 can inhibit glucose-induced cell proliferation and DNA synthesis in AoSMC and A10 cells. CGP-53353 can be used for researching atherosclerosis of diabetic patients .

HY-170572

PB01	Dipeptidyl Peptidase Reactive Oxygen Species	Metabolic Disease
PB01 is a DPP-4 inhibitor with an IC₅₀ of 15.66 nM. It effectively inhibits high glucose-induced ROS production and mitochondrial superoxide formation while significantly reducing cellular DPP-4 expression. PB01 can also significantly lower blood glucose levels in diabetic mice. Additionally, PB01 demonstrates good safety, exhibiting almost no cytotoxicity at a concentration of 100 μM. PB01 holds potential for research in the field of diabetes .

HY-B1350A

Fusidic acid sodium salt 2 Publications Verification Sodium fusidate; SQ-16360	Bacterial Antibiotic Interleukin Related	Infection Inflammation/Immunology
Fusidic acid sodium salt is an orally available antibacterial agent that inhibits bacterial protein synthesis by preventing the release of translation elongation factor G (EF-G) from ribosomes. Fusidic acid sodium salt inhibits the inhibitory and activating effects of interleukins IL-1 and IL-6 on glucose-induced insulin production and exhibits antidiabetic effects in a rat model. Fusidic acid sodium salt improves the symptoms of colitis in rats and inhibits the growth of Toxoplasma gondii and Listeria monocytogenes EGD in vitro, but not in mice .

HY-P3641

Kisspeptin 13	GnRH Receptor	Neurological Disease Metabolic Disease
Kisspeptin 13 inhibits glucose-induced insulin secretion with an IC₅₀ of 1.2 nM. Kisspeptin 13 activates the hypothalamic-pituitary-adrenal (HPA) axis, causes hyperthermia, motor behavior and anxiety in rats. Kisspeptin 13 interacts with α2-adrenergic and 5-HT2 serotonin receptors, exhibits antidepressant efficacy. Kisspeptin 13 is an activator for GPR54 and GnRH receptor, which enhances memory and can be used in Alzheimer's disease research .

HY-13755

Sulforaphane Maximum Cited Publications 48 Publications Verification	HDAC Keap1-Nrf2 Apoptosis Bcl-2 Family Caspase Reactive Oxygen Species	Inflammation/Immunology Cancer
Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties .

HY-P3641A

Kisspeptin 13 TFA	GnRH Receptor	Neurological Disease Metabolic Disease
Kisspeptin 13 TFA is the TFA salt form of Kisspeptin 13 (HY-P3641). Kisspeptin-13 TFA inhibits glucose-induced insulin secretion with an IC₅₀ of 1.2 nM. Kisspeptin 13 TFA activates the hypothalamic-pituitary-adrenal (HPA) axis, causes hyperthermia, motor behavior and anxiety in rats. Kisspeptin 13 TFA interacts with α2-adrenergic and 5-HT2 serotonin receptors, exhibits antidepressant efficacy. Kisspeptin 13 TFA is an activator for GPR54 and GnRH receptor, which enhances memory and can be used in Alzheimer's disease research .

HY-113513

5-HEPE	Others	Cancer
5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.

HY-P0055

GLP-1(7-37) 3 Publications Verification	GCGR	Metabolic Disease
GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

HY-P0055A

GLP-1(7-37) acetate 3 Publications Verification	GCGR	Metabolic Disease
GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion .

HY-P5796

FS-2	Calcium Channel	Neurological Disease
FS-2 is a potent and specific L-type Ca_V channel inhibitor. FS-2 inhibits high K ⁺ or glucose induced L-type Ca ²⁺ influx in RIN beta cells .

HY-161501

3-Fluoro-evodiamine glucose	GLUT Topoisomerase Apoptosis	Cancer
3-Fluoro-evodiamine glucose (Compound 8) is an evodiamine-glucose conjugate. 3-Fluoro-evodiamine glucose activates the expression of glucose transporter 1 (GLUT1), and inhibits topoisomerase I/II. 3-Fluoro-evodiamine glucose induces apoptosis and arrests the cell cycle at G2/M phase. 3-Fluoro-evodiamine glucose exhibits antitumor efficacy in vivo and in vitro, without significant toxicity .

HY-N0330

Momordin Ic 3 Publications Verification	Apoptosis Autophagy PI3K c-Myc	Metabolic Disease Inflammation/Immunology Cancer
Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl₄ (HY-Y0298) induced hepatotoxicity and anti-tumor activity .

HY-N0330R

Momordin Ic (Standard)	Apoptosis Autophagy PI3K c-Myc	Metabolic Disease Inflammation/Immunology Cancer
Momordin Ic (Standard) is the analytical standard of Momordin Ic. This product is intended for research and analytical applications. Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl4 (HY-Y0298) induced hepatotoxicity and anti-tumor activity .

Cat. No.	Product Name	Target	Research Area